AstraZeneca PLC - Asset Resilience Ratio

Latest as of December 2025: 0.03%

AstraZeneca PLC (AZN) has an Asset Resilience Ratio of 0.03% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read AZN liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets

GBX30.00 Million
≈ $3.65K USD Cash + Short-term Investments

Total Assets

GBX114.07 Billion
≈ $13.88 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (1990–2025)

This chart shows how AstraZeneca PLC's Asset Resilience Ratio has changed over time. See net assets of AstraZeneca PLC for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down AstraZeneca PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AstraZeneca PLC (AZN) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents GBX0.00 0%
Short-term Investments GBX30.00 Million 0.03%
Total Liquid Assets GBX30.00 Million 0.03%

Asset Resilience Insights

  • Limited Liquidity: AstraZeneca PLC maintains only 0.03% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

AstraZeneca PLC Industry Peers by Asset Resilience Ratio

Compare AstraZeneca PLC's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
AstraZeneca PLC
NASDAQ:AZN
Drug Manufacturers - General 5.03%
Novartis AG
MX:NVSN
Drug Manufacturers - General 0.09%
Novartis AG ADR
NYSE:NVS
Drug Manufacturers - General 10.03%
Pfizer Inc
SA:PFIZ34
Drug Manufacturers - General 7.18%
Virbac SA
PA:VIRP
Drug Manufacturers - General 0.23%
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
Drug Manufacturers - General 0.53%
Firebrick Pharma Ltd
AU:FRE
Drug Manufacturers - General 0.29%
Eli Lilly and Company
SA:LILY34
Drug Manufacturers - General 8.63%

Annual Asset Resilience Ratio for AstraZeneca PLC (1990–2025)

The table below shows the annual Asset Resilience Ratio data for AstraZeneca PLC.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.03% GBX30.00 Million
≈ $3.65K
GBX114.07 Billion
≈ $13.88 Million
-0.13pp
2024-12-31 0.16% GBX165.83 Million
≈ $20.18K
GBX104.03 Billion
≈ $12.66 Million
+0.04pp
2023-12-31 0.12% GBX120.97 Million
≈ $14.72K
GBX101.12 Billion
≈ $12.30 Million
+0.04pp
2022-12-31 0.08% GBX77.00 Million
≈ $9.37K
GBX96.48 Billion
≈ $11.74 Million
+0.01pp
2021-12-31 0.07% GBX68.72 Million
≈ $8.36K
GBX105.36 Billion
≈ $12.82 Million
-0.17pp
2020-12-31 0.24% GBX159.22 Million
≈ $19.37K
GBX66.73 Billion
≈ $8.12 Million
-1.14pp
2019-12-31 1.38% GBX849.00 Million
≈ $103.30K
GBX61.38 Billion
≈ $7.47 Million
-0.02pp
2018-12-31 1.40% GBX849.00 Million
≈ $103.30K
GBX60.65 Billion
≈ $7.38 Million
-0.54pp
2017-12-31 1.94% GBX1.23 Billion
≈ $149.66K
GBX63.35 Billion
≈ $7.71 Million
+0.53pp
2016-12-31 1.41% GBX884.00 Million
≈ $107.56K
GBX62.53 Billion
≈ $7.61 Million
+0.39pp
2015-12-31 1.02% GBX613.00 Million
≈ $74.58K
GBX60.06 Billion
≈ $7.31 Million
+0.99pp
2014-12-31 0.03% GBX20.00 Million
≈ $2.43K
GBX58.59 Billion
≈ $7.13 Million
-1.43pp
2013-12-31 1.47% GBX820.48 Million
≈ $99.83K
GBX55.90 Billion
≈ $6.80 Million
-0.07pp
2012-12-31 1.54% GBX823.00 Million
≈ $100.14K
GBX53.53 Billion
≈ $6.51 Million
-6.50pp
2011-12-31 8.04% GBX4.25 Billion
≈ $516.86K
GBX52.83 Billion
≈ $6.43 Million
+5.42pp
2010-12-31 2.62% GBX1.47 Billion
≈ $179.19K
GBX56.13 Billion
≈ $6.83 Million
-0.11pp
2009-12-31 2.73% GBX1.50 Billion
≈ $182.71K
GBX54.92 Billion
≈ $6.68 Million
+2.51pp
2008-12-31 0.22% GBX105.00 Million
≈ $12.78K
GBX46.95 Billion
≈ $5.71 Million
-0.14pp
2007-12-31 0.37% GBX176.67 Million
≈ $21.50K
GBX47.96 Billion
≈ $5.83 Million
-1.83pp
2006-12-31 2.20% GBX657.29 Million
≈ $79.97K
GBX29.93 Billion
≈ $3.64 Million
-4.36pp
2005-12-31 6.56% GBX1.63 Billion
≈ $198.18K
GBX24.84 Billion
≈ $3.02 Million
-9.85pp
2004-12-31 16.41% GBX4.21 Billion
≈ $512.24K
GBX25.65 Billion
≈ $3.12 Million
+2.76pp
2003-12-31 13.65% GBX3.22 Billion
≈ $391.54K
GBX23.57 Billion
≈ $2.87 Million
-4.71pp
2002-12-31 18.36% GBX3.96 Billion
≈ $482.06K
GBX21.58 Billion
≈ $2.63 Million
+1.51pp
2001-12-31 16.86% GBX3.12 Billion
≈ $379.37K
GBX18.50 Billion
≈ $2.25 Million
-1.74pp
2000-12-31 18.60% GBX3.43 Billion
≈ $417.43K
GBX18.45 Billion
≈ $2.24 Million
+4.17pp
1999-12-31 14.43% GBX2.86 Billion
≈ $347.86K
GBX19.82 Billion
≈ $2.41 Million
+12.94pp
1998-12-31 1.48% GBX274.00 Million
≈ $33.34K
GBX18.48 Billion
≈ $2.25 Million
-7.02pp
1997-12-31 8.50% GBX704.23 Million
≈ $85.68K
GBX8.28 Billion
≈ $1.01 Million
-5.82pp
1996-12-31 14.32% GBX1.23 Billion
≈ $149.19K
GBX8.56 Billion
≈ $1.04 Million
+1.97pp
1995-12-31 12.35% GBX971.94 Million
≈ $118.26K
GBX7.87 Billion
≈ $957.52K
+8.36pp
1994-12-31 3.99% GBX292.36 Million
≈ $35.57K
GBX7.32 Billion
≈ $890.42K
+1.31pp
1993-12-31 2.69% GBX199.69 Million
≈ $24.30K
GBX7.42 Billion
≈ $903.30K
-0.03pp
1992-12-31 2.72% GBX168.35 Million
≈ $20.48K
GBX6.19 Billion
≈ $752.91K
-0.10pp
1991-12-31 2.82% GBX179.63 Million
≈ $21.86K
GBX6.36 Billion
≈ $774.08K
-5.11pp
1990-12-31 7.94% GBX484.16 Million
≈ $58.91K
GBX6.10 Billion
≈ $742.34K
--
pp = percentage points

About AstraZeneca PLC

LSE:AZN UK Drug Manufacturers - General
Market Cap
$2.55 Billion
GBX20.95 Trillion GBX
Market Cap Rank
#5431 Global
#11 in UK
Share Price
GBX13512.00
Change (1 day)
-3.13%
52-Week Range
GBX10022.00 - GBX15542.00
All Time High
GBX15542.00
About

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo,… Read more